TET Systems and Pharmasset Settle Patent Litigation

26-Aug-2009 - USA

TET Systems Holding GmbH & Co. KG announced that TET Systems and Pharmasset, Inc. have settled patent litigation between the companies surrounding TET Systems’ patented gene expression technology. As part of the confidential settlement, the parties agreed to dismiss the litigation with prejudice and Pharmasset agreed to take a license under TET Systems’ portfolio of systems for efficient, precise, and reversible control over both timing and level of gene expression in eukaryotic cells. Under the terms of the agreement, Pharmasset will, among other things, make an undisclosed payment to TET Systems.

Other news from the department politics & laws

Most read news

More news from our other portals

Fighting cancer: latest developments and advances